Eli Lilly and Company
For nearly 150 years, we’ve made significant and game-changing progress on our mission to make life better for people around the world. We’ve remained headquartered in Indianapolis, Indiana, since our founding on May 10, 1876, but our employees now work in countries around the world.
And thanks to the dedication of our diverse global team, we’ve been able to answer the call for new medicines to help solve some of the world’s most significant health challenges
When you’re on a mission to do what’s never been done before, you seek people willing to challenge the status quo of medicine. Those willing to relentlessly pursue what’s next, all in the name of health above all. #WeAreLilly
We are Lilly
Why do our employees love coming to work each and every day? Here’s what they have to say.
47,000 global employees coming together from diverse backgrounds to create medicines that make life better for people around the world. Get to know Team Lilly through our Powered by Purpose series.
NEWS
To help with your job search, here are 10 biopharma companies hiring for Artificial Intelligence and Machine Learning (AI/ML) roles now.
Clinical results for experimental treatments in Alzheimer’s, ALS and more are expected over the coming months. BioSpace highlights a few of the more highly anticipated datasets.
The regulator found no issues with mirikizumab’s clinical or safety data.
After Eli Lilly announced it would take measures to cap insulin prices, Novo Nordisk will reportedly follow suit. There may be strategic reasoning behind these moves.
Data released Wednesday from the Phase III A4 study showed solanezumab fell short of its primary endpoint, failing to slow cognitive decline in patients with preclinical Alzheimer’s disease.
Eli Lilly is expanding its pain management pipeline with a new asset from Belgium-based Confo Therapeutics targeting the angiotensin II type 2 receptor.
Rezpegaldesleukin, Lilly’s and Nektar Therapeutics’ candidate for systemic lupus erythematosus, fell short of its primary efficacy endpoint in the Phase II ISLAND trial.
The FDA granted Eli Lilly’s Jaypirca accelerated approval for the treatment of adults with relapsed or refractory mantle cell lymphoma.
The FDA’s approval of Biogen and Eisai’s Leqembi and subsequent decision not to approve Eli Lilly’s donanemab have sparked debate anew about the anti-amyloid theory in Alzheimer’s.
JOBS
IN THE PRESS